X T L Biopharmaceuticals Ltd (NASDAQ:XTLB)’s stock price dropped 5.1% on Monday . The stock traded as low as $1.31 and last traded at $1.31, approximately 200 shares were traded during trading. A decline of 94% from the average daily volume of 3,590 shares. The stock had previously closed at $1.38.
Separately, ValuEngine upgraded shares of X T L Biopharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd.
The stock has a market cap of $6.74 million, a PE ratio of 1.14 and a beta of 1.09. The company’s 50 day moving average is $1.51 and its 200-day moving average is $1.89.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.
Featured Story: Cost of Equity For A Business, Investors
Receive News & Ratings for X T L Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X T L Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.